Supernus Pharmaceuticals, Inc. (LON:0LB2)

Market Cap	2.16B +24.1%
Revenue (ttm)	507.02M +4.5%
Net Income	-14.22M
EPS	-0.25
Shares Out	n/a
PE Ratio	n/a
Forward PE	27.61
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1
Average Volume	53
Open	50.75
Previous Close	50.80
Day's Range	50.75 - 50.75
52-Week Range	29.68 - 57.60
Beta	0.68
RSI	54.28
Earnings Date	Feb 25, 2026

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes products for the treatment of central nervous system (CNS) diseases in the United States. The company offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 2005
• Employees: 674
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0LB2

Financial Performance

In 2024, Supernus Pharmaceuticals's revenue was $661.82 million, an increase of 8.94% compared to the previous year's $607.52 million. Earnings were $73.87 million, an increase of 5512.84%.

Financial numbers in USD